Table 1. Baseline characteristics of patients (ITT population).
| Category | Placebo (n = 39) | Avanafil 50 mg (n = 40) | Avanafil 100 mg (n = 40) | Avanafil 200 mg (n = 39) | Total (n = 158) |
|---|---|---|---|---|---|
| Age, yr | |||||
| Mean (SD) | 56.7 (9.0) | 55.7 (7.6) | 57.2 (8.0) | 56.1 (6.7) | 56.4 (7.8) |
| Median | 58 | 57 | 59 | 57 | 58 |
| Min–Max | 29–69 | 41–67 | 33–69 | 42–67 | 29–69 |
| Smoking, No. (%) | |||||
| Yes | 10 (25.6) | 8 (20.0) | 8 (20.0) | 9 (23.1) | 35 |
| No | 29 (74.4) | 32 (80.0) | 32 (80.0) | 30 (76.9) | 123 |
| Alcohol, No. (%) | |||||
| Yes | 21 (53.9) | 27 (67.5) | 23 (57.5) | 21 (53.9) | 92 |
| No | 18 (46.2) | 13 (32.5) | 17 (42.5) | 18 (46.2) | 66 |
| EF domain | |||||
| Mean (SD) | 15.1 (3.0) | 16.0 (3.0) | 15.7 (3.0) | 16.0 (3.1) | 15.7 (3.0) |
| Median | 15 | 16 | 16 | 16 | 16 |
| Min–Max | 11–22 | 11–24 | 11–21 | 11–25 | 11–25 |
| Duration of ED, yr | |||||
| Mean (SD) | 5.9 (4.7) | 4.8 (4.0) | 5.2 (5.0) | 4.6 (3.4) | 5.1 (4.3) |
| Median | 5.0 | 4.0 | 3.1 | 3.5 | 4.0 |
| Min–Max | 0.6–20.0 | 0.6–14.2 | 0.8–23.0 | 0.8–15.0 | 0.6–23.0 |
| Etiology, No. (%) | |||||
| Organic origin | 13 (33.3) | 16 (40.0) | 14 (35.0) | 13 (33.3) | 56 |
| Mixed origin | 23 (59.0) | 22 (55.0) | 21 (52.5) | 22 (56.4) | 88 |
| Psychological origin | 3 (7.7) | 2 (5.0) | 5 (12.5) | 4 (10.3) | 14 |
| Previous treatment for ED, No. (%) | |||||
| None | 15 (38.5) | 22 (55.0) | 24 (60.0) | 24 (61.5) | 85 |
| Experienced | 24 (61.5) | 18 (45.0) | 16 (40.0) | 15 (38.5) | 73 |
| Concomitant diseases, No. (%) | |||||
| None | 6 (15.4) | 7 (17.5) | 6 (15.0) | 5 (12.8) | 24 |
| Yes | 33 (84.6) | 33 (82.5) | 34 (85.0) | 34 (87.2) | 134 |
There were no significant differences between the groups in all parameters.
SD = standard deviation, ITT = intent-to-treat, Min = minimum, Max = maximum, ED = erectile dysfunction, EF = erectile function.